Structure Therapeutics, Inc. (GPCR)
16.13
-0.99
(-5.78%)
USD |
NASDAQ |
Nov 20, 16:00
16.16
+0.03
(+0.19%)
After-Hours: 20:00
Structure Therapeutics Research and Development Expense (TTM) : 370.83M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 370.83M |
| June 30, 2026 | 294.98M |
| March 31, 2026 | 249.67M |
| December 31, 2025 | 225.89M |
| September 30, 2025 | 190.27M |
| June 30, 2025 | 164.07M |
| March 31, 2025 | 131.19M |
| December 31, 2024 | 108.90M |
| Date | Value |
|---|---|
| September 30, 2024 | 95.72M |
| June 30, 2024 | 80.37M |
| March 31, 2024 | 77.54M |
| December 31, 2023 | 70.01M |
| September 30, 2023 | 58.17M |
| June 30, 2023 | 50.79M |
| March 31, 2023 | 40.09M |
| December 31, 2022 | 36.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly & Co. | 15.38B |
| Novo Nordisk A/S | 8.024B |
| Merck & Co., Inc. | 27.55B |
| Prestige Consumer Healthcare, Inc. | -- |
| Pfizer Inc. | 11.29B |